Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multifocal inflammatory leukoencephalopathy associated with levamisole therapy

D W Kimmel1, E F Wijdicks, M Rodriguez

  • 1Department of Neurology, Mayo Clinic, Rochester, MN 55905.

Neurology
|February 1, 1995
PubMed
Summary

Levamisole, used for melanoma treatment, can cause demyelinating disease. This neurological side effect, characterized by confusion and ataxia, improved after discontinuing levamisole therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Caudate hemorrhage as a possible complication of midodrine-induced supine hypertension.

Mayo Clinic proceedings·2002
Same author

Mechanisms of intracerebral hemorrhage after carotid endarterectomy.

Journal of neurosurgery·2002
Same author

Rapid weaning from mechanical ventilator in acute cervical cord multiple sclerosis lesion after steroids.

Anesthesia and analgesia·2001
Same author

Neurotoxicity of immunosuppressive drugs.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2001
Same author

High-grade carotid stenosis detected before general surgery: is endarterectomy indicated?

Neurology·2001

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Background:

  • Adjuvant therapy for malignant melanoma often involves chemotherapy agents.
  • Levamisole is an immunomodulatory drug sometimes used in cancer treatment protocols.
  • Neurological side effects of cancer therapies require careful monitoring.

Observation:

  • A patient undergoing adjuvant levamisole therapy for melanoma developed cerebral demyelinating disease.
  • Symptoms included progressive confusion and ataxia over three weeks.
  • Magnetic resonance imaging (MRI) revealed multifocal white matter lesions with gadolinium enhancement.

Findings:

  • Cerebrospinal fluid (CSF) analysis showed an inflammatory profile.
  • Discontinuation of levamisole and a course of corticosteroids led to dramatic clinical and MRI improvement.

Related Experiment Videos

  • The findings suggest levamisole may contribute to or cause leukoencephalopathy.

    • Implications:

    • Levamisole should be considered a potential cause of demyelinating disease in cancer patients.
    • This case highlights the importance of recognizing drug-induced neurological toxicity.
    • Further investigation into levamisole's neurotoxic potential is warranted.